Zacks Investment Research
05 Jun 2026, 18:55 UTC · 2h ago
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
Zacks Investment Research
05 Jun 2026, 18:55 UTC · 2h ago
Story key points
3 claims · impact-rated
Agenus's valuation is primarily driven by the BATTMAN phase III trial of the botensilimab and balstilimab (BOT+BAL) combination for refractory MSS/pMMR metastatic colorectal cancer. — The company has explicitly positioned this program as its core value driver, making the trial's outcome a binary event for the stock.
+0.60Early-stage data for BOT+BAL in MSS mCRC patients without liver metastases showed a two-year overall survival rate of approximately 42% and a median overall survival of nearly 21 months. — These survival signals provide the clinical justification for the expensive phase III effort and suggest potential efficacy in a hard-to-treat population.
+0.40Agenus has paused certain non-core programs to prioritize the BOT+BAL combination and evaluate funding and partnership paths. — Strategic realignment suggests a focus on capital preservation and the most promising asset, though it indicates a reliance on external funding or partners.
+0.20Continue reading
6 related stories
Top 3 movers · tap to explore
Ticker attribution
Model heads
The company is advancing a promising combination therapy with positive early survival signals in a high-unmet-need cancer market.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
1 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Reuters
29m ago
